Nistat

Quick links to important sections

Nistat

Treatment option: Infection, Oral Cavity

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nistat

What is Nistat? Overview and Quick Facts

Property Description
Active Ingredient Nystatin
Form Oral tablets, suspension, cream, powder
Pharmacological Class Antifungal (Polyene macrolide)
Common Use Control of localized mycotic infections
Origin Natural (derived from Streptomyces noursei)

What Type of Medicine is Nistat?

Nistat is an antifungal medication whose active ingredient is Nystatin, a polyene macrolide agent used to control infections caused by susceptible fungi and yeasts. The active compound, Nystatin, is classified as a polyene macrolide, reflecting its complex chemical structure and its distinctive natural origin, having been synthesized by the bacterium Streptomyces noursei. This specific origin differentiates Nystatin from purely synthetic antifungal agents. Nystatin is clinically recognized for its safety profile and confirmed efficacy, leading to its inclusion on the WHO Model List of Essential Medicines.


Nistat Composition and Forms

The medication is a single-ingredient product, containing only the active ingredient Nystatin, and is prepared in multiple forms optimized for localized application. Nistat is available in forms such as oral tablets and oral suspension for infections affecting the mouth or digestive tract, and various topical preparations like cream and powder for external use. This formulation strategy is a key differentiating factor, as Nystatin exhibits minimal systemic absorption, meaning it works primarily at the site of contact. The various preparations are tailored to target common patient groups, such as those with oropharyngeal candidiasis or cutaneous candidiasis, delivering the therapeutic agent directly where it is needed.


General Therapeutic Purpose of Nystatin

The general therapeutic purpose of Nystatin is to neutralize the growth and viability of fungal cells responsible for localized infections. This antifungal action is supported by pharmacological properties where Nystatin selectively targets and disrupts the physical structure of the fungal cell membrane. The compound achieves this by binding to the essential ergosterol found in fungal cells, initiating a fungistatic and fungicidal effect. This mechanism ensures a targeted response against fungal pathogens, providing effective relief for the discomfort associated with localized yeast and fungal overgrowths.

Regulatory References

  1. Nystatin in WHO Essential Medicines List (eEML)
  2. Nystatin Oral: MedlinePlus Drug Information

What side effects are possible with Nistat?

Possible Side Effects and Safety Information

The safety profile for Nistat (Nystatin) is primarily shaped by its negligible systemic absorption, meaning that adverse effects are predominantly localized to the site of application. Regulatory documents classify side effects by frequency and the body system affected, providing a structured understanding of potential risks.


Official Adverse Reactions and Classifications

Adverse events are often observed in the Gastrointestinal Disorders system for oral forms (suspension, tablets) and the Skin and Subcutaneous Tissue Disorders system for topical forms.

Classification Examples of Reactions
Common Nausea, vomiting, diarrhea, gastrointestinal upset, abdominal pain, local irritation.
Rare / Very Rare Severe skin reactions, including Stevens-Johnson Syndrome (SJS), angioedema (swelling), tachycardia (fast heart rate), and bronchospasm.

Population Safety and Restrictions

Nistat is contraindicated in patients with a known history of hypersensitivity to the active ingredient, Nystatin, or any components in the formulation. This restriction is administration-agnostic and applies to all forms of the medicine.

Due to minimal systemic exposure, dose adjustment is not generally required for patients with renal or hepatic impairment. However, official safety notes state that patients with renal insufficiency may occasionally develop measurable concentrations of Nystatin in the plasma.

The medication is not indicated for the treatment of systemic mycoses (widespread internal fungal infections). Gastrointestinal symptoms are also documented as potentially more noticeable with high oral doses.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Overdose Manifestations

The official regulatory profile for Nistat (Nystatin) is defined by its negligible absorption from the gastrointestinal tract. Consequently, overdose or accidental ingestion is documented as causing no systemic toxicity. The clinical manifestations reported in official labeling are limited to localized gastrointestinal effects.

Symptoms reported following the ingestion of high doses include nausea, vomiting, diarrhea, and general gastrointestinal upset or distress. Specifically, oral doses in excess of 5 million units daily have been associated with these localized manifestations. There are no reports of serious toxic effects or life-threatening systemic outcomes listed in the official documents.

Emergency Actions Mandated by Regulators

Immediate action is required if an overdose is suspected. According to regulatory instructions, individuals must seek emergency medical attention or call a Poison Help center immediately.

Urgent medical services must be contacted if the person who has taken an overdose has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Treatment for overdose is generally described as supportive and symptomatic, and no specific antidote is mentioned in the official prescribing information.

A pharmacokinetic consideration notes that in patients with underlying renal insufficiency, significant plasma concentrations of Nystatin may occasionally occur with oral therapy, a point noted in regulatory documents regarding systemic exposure.

Therapeutic Uses of Nistat

Nistat is commonly used to help with fungal infections of the inside of the mouth and lining of the digestive tract. The medication is applied across therapeutic domains involving fungal pathogens.

Therapeutic Scope and Symptom Relief

This medication is primarily applied in addressing superficial fungal infections caused by the Candida species in localized areas. It is relevant in conditions presenting with acute episodes, helping manage symptom clusters that may become intense or disruptive. The therapeutic domain includes infections of the mouth and throat (oral thrush), the skin (cutaneous candidiasis), and certain gastrointestinal yeast infections.

When used to manage the localized infection and easing pronounced symptoms, Nistat provides supportive relief when symptoms interfere with routine activities. It contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

“Supports the patient during difficult episodes by easing distress.”

Quick Fact: Relevant for Managing Irritation and Pain (The medication is generally considered relevant for managing symptoms that interfere with daily functioning, such as those that affect eating or speaking.)

Support for Functional Stability

By assisting with the management of the localized infection and easing pronounced symptoms, Nistat supports general well-being during symptomatic phases. This is helpful in situations requiring additional symptomatic assistance and helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility for Nystatin, based strictly on authoritative regulatory documents.

Contraindications and Restrictions

Nystatin must not be used (Contraindicated) by individuals with a known history of hypersensitivity or allergic reaction to nystatin or any component of the formulation.

Populations Restricted from Use:

  • It is strictly not for the treatment of systemic mycoses (widespread internal fungal infections), as the drug is poorly absorbed into the bloodstream. Its use is limited to local or topical infections.
  • The use of solid oral forms (like lozenges or tablets) is generally restricted or not recommended for children up to 5 years of age due to the risk of choking or aspiration; the oral suspension is typically used instead.
  • Caution is advised for patients with renal insufficiency receiving conventional oral therapy, as significant plasma levels may occasionally occur.

Use in Physiological States

  • Pregnancy: Nystatin is generally classified as Pregnancy Category C by the FDA. It should be given to a pregnant individual only if clearly needed and the potential benefit outweighs the potential risk.
  • Lactation: Caution is recommended for nursing mothers as it is not known whether nystatin is excreted in human milk.

What should I know about interactions with other medicines?

Nistat Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions Probiotic organisms/supplements containing live yeast; specific allogeneic cultured tissue products.
Specific interacting medicines (if explicitly listed) Substances containing Saccharomyces boulardii or similar live yeast preparations.
Mechanistic basis of interactions (only if stated in label) Local Antagonism (Pharmacodynamic Conflict): Antifungal activity directly reduces the viability of co-administered live fungal/yeast products. Physical Degradation: The agent may interfere with the structure of specific cultured biological products.
Interaction-related restrictions Contraindication for local co-administration with certain allogeneic cultured tissue products.

Interaction Classifications (High-Level)

Classification Official Regulatory Information
Interaction severity classification (as defined in official documents) Contraindicated (with specific cultured tissue products); Clinically relevant local antagonism (with probiotic yeasts); None known for systemic drug-drug interactions.
Interaction-context constraints (as defined in official documents) Interactions are restricted to the local site of administration.

Resulting Interaction Structure

Official regulatory documents state that no clinically significant interactions involving systemic metabolism, such as those mediated by CYP enzymes or drug transporters, are known. This is directly related to Nistat's fundamental pharmacokinetic property of having negligible systemic absorption. The only documented interaction concerns are local, including a formal contraindication for concurrent local use with specific allogeneic cultured tissue products. Furthermore, Nistat's direct antifungal action may result in a reduction of effect for co-administered probiotic supplements that contain live yeast organisms. No interactions with food or alcohol are officially known or documented in the regulatory labeling.

Mechanism of Action

Direct Disruption of Fungal Cell Structure

The mechanism of action is defined by a direct, physical interaction with the fungal cell. The drug molecule, a polyene macrolide, exhibits high affinity for ergosterol, the principal sterol in the fungal cell membrane. This binding initiates the formation of aggregated drug molecules that insert into the membrane, creating ion-permeable channels or pores. This interaction is classified as an ionophore effect, which immediately compromises the structural integrity of the cell boundary.


Mechanistic Cascade and Localized Effect

This membrane disruption triggers a cascade beginning with the uncontrolled efflux of potassium ions (K^+) and other essential small molecules from the cell. This loss of cellular contents and the resulting collapse of the electrochemical gradient compromises the fungal cell's viability and osmotic balance, leading directly to fungal cell death via lysis. Due to the drug's negligible absorption into systemic circulation, its entire mechanistic effect is localized, resulting in a controlled reduction of the fungal pathogen load at the site of contact.

Dosage and Administration Information

How Nistat is Used: Official Administration Guidelines

Nistat (Nystatin) administration is strictly localized, with usage patterns differing based on the formulation and site of application.

Administration and Dosage Schedules

Administration Route Standard Adult Dose Frequency
Oral Suspension 400,000 to 600,000 units per dose Four times daily (q.i.d.)
Oral Tablets (Intestinal) 500,000 to 1,000,000 units per dose Three times daily (t.i.d.)
Topical Cream/Ointment Apply to affected areas Twice daily (b.i.d.)

Procedural and Population-Specific Instructions

Oral Administration Technique

For the oral suspension, the medication must be shaken well before measurement. Proper application involves placing approximately half of the dose in each side of the mouth. The preparation should be retained in the mouth as long as possible (e.g., swished or gargled) before swallowing, or allowing lozenges/tablets to dissolve slowly to maximize local contact.

Duration of Therapy

Treatment is generally continued for a minimum of 48 hours after symptoms have clinically disappeared to ensure eradication of the infection. Topical preparations are applied until healing is complete.

Pediatric Dosing Rules

Specific dosing for infants includes 200,000 units (2 mL) four times daily, with a lower dose of 100,000 units (1 mL) four times daily for premature and low-birth-weight neonates. In infants, feeding should be avoided for 5 to 10 minutes following administration to maintain drug contact.

Missed Dose

If a dose is missed, it should be taken as soon as remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped to return to the regular regimen; double doses should not be taken.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies for Nistat


Evidence for Use in Oropharyngeal Candidiasis (Oral Thrush)

The research landscape for the treatment of oral candidiasis primarily involves short-term Randomized Controlled Trials (RCTs) and systematic reviews. Nystatin was evaluated in a range of groups, including infants, children, adults with dentures, and immunocompromised individuals. Studies focused on outcomes related to physical discomfort, such as the visible resolution of oral lesions and the status of fungal presence (mycological cure).

Findings describe patterns where use was associated with measured changes in symptom and lesion status compared to a placebo or non-active control. However, in research involving high-risk groups, such as adults with severe immune compromise, measurements of fungal clearance were compared to those reported for newer, systemically active agents. Evidence quality varies across studies, and many original trials have modest sample sizes.

Evidence for Use in Cutaneous Candidiasis (Skin Fungal Infection)

For cutaneous candidiasis, the evidence supporting Nistat's topical forms comes from a combination of clinical experience, historical regulatory evaluations, and comparative studies. Research was studied for conditions where symptoms may vary in intensity, such as redness and irritation. The main outcomes examined were clinical responses and mycological status.

What Research Gaps and Uncertainties Remain

Despite its long history, the research base contains several limitations. Comparative evidence is lacking in the form of modern, large-scale RCTs that rigorously compare Nystatin directly against all currently available topical and systemic antifungals. Research still indicates a gap regarding the optimal dosage and duration of Nystatin use for both treatment and prophylaxis, with definitive comparative trial data still limited. Furthermore, long-term effects are not fully established, and there is limited information for outcomes related to the persistence of fungal presence after treatment is complete.

Key Studies & References

  1. Nystatin Drug Label and Monograph - U.S. Food and Drug Administration (FDA)
  2. Nystatin - Drug Information - MedlinePlus (National Institutes of Health)
  3. WHO Model List of Essential Medicines (Nystatin Listing)

Frequently Asked Questions (FAQ)

Common questions about Nistat (FAQ)

Q: How does the use of Nistat differ from other common antifungal medications?

The key difference described in official product information is that Nistat is not absorbed into the bloodstream to a significant degree. It is described as working locally, only at the site of contact, which is why it is used for infections on the skin or mucous membranes and not for widespread internal fungal infections. Studies and official documents also indicate that Nistat is often used as a first-line local treatment for certain infections.


Q: Is Nistat meant for short-term use or long-term management?

Official regulatory documents primarily guide Nistat for short-term use to treat acute infections, such as for a course of around one week. However, the product information states that it is well tolerated even with prolonged therapy in some populations. Evidence also indicates that Nistat is sometimes prescribed for prophylaxis (preventative use) in specific high-risk clinical settings.


Q: Can Nistat be crushed or mixed with food if a person has trouble swallowing pills?

Official instructions advise that the oral suspension form is not to be mixed with food or other drinks. The solid forms, such as lozenges or tablets, are described as needing to be held in the mouth and dissolved slowly to ensure proper drug contact. Regulatory information does not provide instructions for crushing the tablets.


Q: Is Nistat ever prescribed for preventative use in high-risk patients?

Yes. Official documentation and clinical studies confirm that Nystatin is used for prophylaxis, which is preventative treatment, in certain high-risk groups. This use is typically seen in patients, such as those undergoing specific intensive medical treatments or low-birth-weight infants.


Q: Is Nistat considered a generic drug or a brand-name medicine?

Official sources confirm that the active ingredient, Nystatin, is available in both generic forms and under various brand names. This means Nistat may be supplied as a generic product or as a specific trademarked preparation.


Q: What is the typical time frame for Nistat to begin showing signs of working?

Regulatory-cited patient information suggests that individuals using the oral liquid form may start to notice signs of improvement after approximately two days of consistent use.


Q: What happens if the infection seems to come back after stopping Nistat?

The duration of therapy is established in regulatory documents to ensure the complete eradication of the fungal infection. Stopping treatment too soon or skipping doses increases the risk that the infection may not be completely treated, leading to the possibility of a recurrence.


Q: Do official sources describe Nistat as a first-line treatment for its main uses?

Clinical literature cited in regulatory reviews notes that Nistat is generally considered the first-line medication for treating uncomplicated oral candidiasis (oral thrush). This designation is based on its efficacy and limited absorption.


Q: Is it documented that Nistat can cause feelings of dizziness or drowsiness?

Dizziness and drowsiness are not listed as common side effects in the official product information. However, regulatory documents do list them as potential rare and severe symptoms that can occur as part of a serious allergic reaction to the medication.


Q: Is it possible for Nistat to interact with herbal products or dietary supplements?

Official interaction information specifically documents the local antagonism that can occur with live yeast probiotics, as Nistat's antifungal action can reduce their effect. Regulatory documents include general guidance that a healthcare professional should be informed of all prescription and nonprescription medications, supplements, and herbal products a person is taking.


Q: Why do some people report a bad taste or mouth irritation when taking Nistat liquid form?

Regulatory-cited adverse reaction information lists common side effects that can occur at the site of administration. These reported events include oral irritation, a metallic taste, and dry mouth.


Q: Does Nistat contain any common allergens like gluten or lactose?

Official documents provide a list of inactive ingredients (excipients) for each formulation, which typically include things like sucrose, flavorings, and preservatives. These lists do not always include explicit 'gluten-free' or 'lactose-free' claims, but the ingredients are detailed in the regulatory labeling.


Q: Are there any specific safety warnings related to operating heavy machinery while on Nistat?

Official patient information states that because the medicine is minimally absorbed into the bloodstream, Nystatin does not generally affect a person's ability to drive or operate machinery.


Q: Why is Nistat sometimes prescribed when a patient is also taking an antibiotic?

Official sources note that a key risk factor for developing the fungal infection that Nistat treats (candidiasis) is recent antibiotic treatment. Therefore, Nistat may be prescribed at this time either to treat an existing secondary fungal infection or to help prevent one from developing.


Q: What are the signs that Nistat may not be working as expected?

Patient information states that a healthcare professional should be contacted if the condition being treated has not improved within 7 days or if symptoms get worse at any time during the course of treatment.

How should Nistat be stored and disposed of?

Nistat (Nystatin) products must be stored under specific regulatory conditions to maintain stability.

Storage Requirements

Constraint Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Handling/Protection Do not freeze the oral suspension and protect it from light. Avoid excessive heat for all forms.
Container Keep the container tightly closed and store in a light-resistant container for the suspension.
Child Safety Keep out of the reach and sight of children.

Disposal

Any unused or expired Nistat must be disposed of in accordance with local requirements. Regulatory guidance advises against discarding the medicine in wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nistat found in:

A-Z Index: